We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+14.47%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$547M
AUM Growth
+$108M
Cap. Flow
+$78.2M
Cap. Flow %
14.3%
Top 10 Hldgs %
78.46%
Holding
36
New
6
Increased
6
Reduced
2
Closed
10

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$64.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$24.7M
3
ESPR
Esperion Therapeutics
ESPR
+$16.2M
4
WVE icon
Wave Life Sciences
WVE
+$16M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$12M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$41.2M
2
PBYI icon
Puma Biotechnology
PBYI
+$12M
3
ZGNX
Zogenix, Inc.
ZGNX
+$7.01M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.22M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$5.91M

Sector Composition

Rank Sector Weight
1 Healthcare 93.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONTXW
26
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$133K 0.02%
241,644
-67,149
-22% -$39.8K
PBYI icon
27
Puma Biotechnology
PBYI
$404M
– –
-100,000
Closed -$12M
TRAW icon
28
Traws Pharma
TRAW
$6.85M
– –
-43
Closed -$92K
EIGR
29
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-4,611
Closed -$1.52M
RETA
30
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-200,000
Closed -$6.22M
SIOX
31
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-62,500
Closed -$3.44M
CLVS
32
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-500,000
Closed -$41.2M
SBBP
33
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-856,900
Closed -$5.91M
NBRV
34
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-347
Closed -$710K
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
– –
-200,000
Closed -$7.01M
VXX
36
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
– –
-50,000
Closed -$1.96M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Boxer Capital held 36 positions worth $547M, up 25% from $439M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Boxer Capital deployed $78.2M of net new capital in Q4 2017, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 2,726,938 shares worth $68.2M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Medicines Co, an estimated $4.62M trimmed.

  • Boxer Capital's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 2,726,938 shares worth $68.2M.
  • Boxer Capital added most to Esperion Therapeutics in Q4 2017, an estimated $16.2M increase.
  • Boxer Capital's biggest Q4 2017 reduction was Medicines Co, cutting an estimated $4.62M.
  • Boxer Capital fully exited Clovis Oncology, Inc. in Q4 2017, selling an estimated $41.2M.
  • Boxer Capital's ten largest holdings make up 78% of its $547M portfolio in Q4 2017.
  • Boxer Capital opened 6 new positions and closed 10 in Q4 2017.
  • Boxer Capital's portfolio value rose 25% quarter-over-quarter to $547M.

Based on Boxer Capital's 13F filing for Q4 2017, filed 14 Feb 2018.